SBI-5844  (Synonyms: SBI-1275844)

SBI-5844 (SBI-1275844) is a eIF4F complex inhibitor and antiviral agent. SBI-5844 disrupts the assembly of the eIF4F complex and blocks the interaction between eIF4E and eIF4G. SBI-5844 inhibits the synthesis of HCoV-OC43 nucleocapsid protein and reduces the levels of HCoV-OC43 RNA and total protein. SBI-5844 can be used in studies related to human coronavirus OC43 (HCoV-OC43) infection^[1].

SBI-5844 (0-10 µM; 24 h) potently reduces the levels of HCoV-OC43 spike protein and nucleocapsid protein in infected Vero E6 cells^[1].
SBI-5844 (0.08-10 µM; 48 h) dose-dependently and potently reduces the infection rate of HCoV-OC43 in Vero E6 cells^[1].
SBI-5844 (0.625-10 µM; 24 h) potently reduces HCoV-OC43 viral RNA levels in infected Vero E6 cells in a dose-dependent manner, with nearly complete inhibition at 10 µM^[1].
SBI-5844 (5-20 µM) disrupts the eIF4F complex in HCoV-OC43-infected A549 cells by reducing the binding level of eIF4G1-eIF4E and increasing the binding level of 4EBP1-eIF4E^[1].
SBI-5844 (10 µM; 24 h) reduces the interaction between eIF4E and eIF4G in live A549 cells^[1].
SBI-5844 (10 µM; 24 h) potently reduces HCoV-OC43 viral RNA levels and reverses infection-induced changes in host gene expression, aligning the state of both Vero E6 and A549 cells with that of uninfected cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

335.44

C₂₂H₂₅NO₂

832680-32-7

O=C(C)C1=CN(CCCOC2=C(C)C=CC=C2)C3=C1C=CC=C3CC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Feng Y, et al. Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex. Front Pharmacol. 2022;13:1029093. Published 2022 Dec 1.